Publications by authors named "Isis Torrens"

Claim this Profile
I
Impact on antitumor response using a new adjuvant preparation as a component of a human papillomavirus type 16 therapeutic vaccine candidate.
Milaid Granadillo, Aileen Batte, Alain B Alfonso, Aracelys Blanco, Dioslaida Urquiza, Isis Torrens

Vaccine· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LALF -E7, a HPV-16 therapeutic vaccine candidate, forms protein body-like structures when expressed in Nicotiana benthamiana leaves.
Romana J R Yanez, Renate Lamprecht, Milaid Granadillo, Isis Torrens, Elsa Arcalís

Plant Biotechnol J· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression optimization of a cell membrane-penetrating human papillomavirus type 16 therapeutic vaccine candidate in Nicotiana benthamiana.
Romana J R Yanez, Renate Lamprecht, Milaid Granadillo, Brandon Weber, Isis Torrens

PLoS One· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LALF-E7 therapeutic vaccine induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the lungs.
Milaid Granadillo, Aileen Batte, Aracelys Blanco, Alain B Alfonso, José Suárez, Isis Torrens

Clin Exp Metastasis· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression, purification and characterization of a recombinant fusion protein based on the human papillomavirus-16 E7 antigen.
Milaid Granadillo, Aileen Batte, Victoria M Lugo, Alexis Musacchio, Mónica Bequet-Romero, Isis Torrens

Springerplus· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial.
Ana M Solares, Idania Baladron, Thelvia Ramos, Carmen Valenzuela, Zaida Borbon, Isis Torrens

ISRN Obstet Gynecol· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice.
Milaid Granadillo, Maribel G Vallespi, Aileen Batte, Osmany Mendoza, Yordanka Soria, Isis Torrens

Vaccine· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a novel antitumor peptide based on the screening of an Ala-library derived from the LALF(32-51) region.
Maribel G Vallespi, Julio R Fernandez, Isis Torrens, Isbel Garcia, Hilda Garay

J Pept Sci· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl/6 mice.
Mónica Bequet-Romero, Marta Ayala, Boris E Acevedo, Ernesto Galbán Rodríguez, Omar López Ocejo, Isis Torrens

Angiogenesis· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors.
Isis Torréns, Osmany Mendoza, Aileen Batte, Osvaldo Reyes, Luis E Fernández

Vaccine· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the protein kinase 2 (casein kinase 2).
Silvio E Perea, Osvaldo Reyes, Yaquelin Puchades, Osmani Mendoza, Nelson S Vispo, Isis Torrens

Cancer Res· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis